AU2015301278A1 - Biomarkers of polycystic kidney disease and uses thereof - Google Patents
Biomarkers of polycystic kidney disease and uses thereof Download PDFInfo
- Publication number
- AU2015301278A1 AU2015301278A1 AU2015301278A AU2015301278A AU2015301278A1 AU 2015301278 A1 AU2015301278 A1 AU 2015301278A1 AU 2015301278 A AU2015301278 A AU 2015301278A AU 2015301278 A AU2015301278 A AU 2015301278A AU 2015301278 A1 AU2015301278 A1 AU 2015301278A1
- Authority
- AU
- Australia
- Prior art keywords
- pkd
- patient
- cyclin
- levels
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000030761 polycystic kidney disease Diseases 0.000 title claims abstract description 366
- 239000000090 biomarker Substances 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 279
- 108050006400 Cyclin Proteins 0.000 claims abstract description 239
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims abstract description 139
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims abstract description 139
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims abstract description 137
- 238000011282 treatment Methods 0.000 claims abstract description 123
- 108010058545 Cyclin D3 Proteins 0.000 claims abstract description 117
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims abstract description 71
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims abstract description 71
- 108091008611 Protein Kinase B Proteins 0.000 claims abstract description 68
- 102000011260 Retinoblastoma Binding Proteins Human genes 0.000 claims abstract description 56
- 108010023377 Retinoblastoma Binding Proteins Proteins 0.000 claims abstract description 56
- 102000004046 Caspase-2 Human genes 0.000 claims abstract description 51
- 108090000552 Caspase-2 Proteins 0.000 claims abstract description 51
- 102000003861 Ribosomal protein S6 Human genes 0.000 claims abstract description 41
- 108090000221 Ribosomal protein S6 Proteins 0.000 claims abstract description 41
- 108091005981 phosphorylated proteins Proteins 0.000 claims abstract description 17
- 238000012544 monitoring process Methods 0.000 claims abstract description 10
- 108010058546 Cyclin D1 Proteins 0.000 claims abstract description 9
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 claims abstract 30
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 claims abstract 16
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims abstract 2
- 239000003550 marker Substances 0.000 claims description 110
- 102000016736 Cyclin Human genes 0.000 claims description 102
- 210000001808 exosome Anatomy 0.000 claims description 84
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 239000013060 biological fluid Substances 0.000 claims description 67
- 102000004169 proteins and genes Human genes 0.000 claims description 67
- 210000003734 kidney Anatomy 0.000 claims description 46
- 210000002700 urine Anatomy 0.000 claims description 44
- 230000003247 decreasing effect Effects 0.000 claims description 43
- -1 pERK Proteins 0.000 claims description 40
- 229940125921 glucosylceramide synthase inhibitor Drugs 0.000 claims description 38
- 230000003068 static effect Effects 0.000 claims description 30
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 29
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 claims description 25
- 108091000114 ceramide glucosyltransferase Proteins 0.000 claims description 25
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 25
- PXLMHHFXTQNWJZ-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(methoxymethyl)phenyl]pyrimidin-2-yl]-N-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)piperidine-4-carboxamide Chemical compound FC1(CCN(CC1)C1=NC=CC(=N1)C1=CC=C(C=C1)COC)C(=O)NC1(CCN2CCC1CC2)C PXLMHHFXTQNWJZ-UHFFFAOYSA-N 0.000 claims description 20
- DXGMIVPGWLGGPE-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-fluoro-1-[4-[4-(2-fluoroethoxy)phenyl]pyrimidin-2-yl]piperidine-4-carboxamide Chemical compound C1=CC(OCCF)=CC=C1C1=CC=NC(N2CCC(F)(CC2)C(=O)NC2C3CCN(CC3)C2)=N1 DXGMIVPGWLGGPE-UHFFFAOYSA-N 0.000 claims description 20
- 239000004305 biphenyl Substances 0.000 claims description 19
- NMAHPRBPCRWREJ-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(2-methoxyethoxy)phenyl]pyrimidin-2-yl]-N-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)piperidine-4-carboxamide Chemical compound FC1(CCN(CC1)C1=NC=CC(=N1)C1=CC=C(C=C1)OCCOC)C(=O)NC1(CCN2CCC1CC2)C NMAHPRBPCRWREJ-UHFFFAOYSA-N 0.000 claims description 18
- RVNGOAZBZQNZSJ-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(2-methoxyethoxy)phenyl]pyrimidin-2-yl]-n-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)piperidine-4-carboxamide Chemical compound C1=CC(OCCOC)=CC=C1C1=CC=NC(N2CCC(F)(CC2)C(=O)NC2(C)C3CCN(CC3)C2)=N1 RVNGOAZBZQNZSJ-UHFFFAOYSA-N 0.000 claims description 18
- KMMSLXMCZJHSJG-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(methoxymethyl)phenyl]pyrimidin-2-yl]-n-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)piperidine-4-carboxamide Chemical compound C1=CC(COC)=CC=C1C1=CC=NC(N2CCC(F)(CC2)C(=O)NC2(C)C3CCN(CC3)C2)=N1 KMMSLXMCZJHSJG-UHFFFAOYSA-N 0.000 claims description 18
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 18
- KWLRZSSADMGVLE-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(2-fluoroethoxy)phenyl]pyrimidin-2-yl]-n-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)piperidine-4-carboxamide Chemical compound C1CN(CC2)CCC2C1(C)NC(=O)C(CC1)(F)CCN1C(N=1)=NC=CC=1C1=CC=C(OCCF)C=C1 KWLRZSSADMGVLE-UHFFFAOYSA-N 0.000 claims description 17
- XQHFDBAIOCBLAT-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(2-methoxyethoxymethyl)phenyl]pyrimidin-2-yl]-N-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)piperidine-4-carboxamide Chemical compound COCCOCc1ccc(cc1)-c1ccnc(n1)N1CCC(F)(CC1)C(=O)NC1(C)CN2CCC1CC2 XQHFDBAIOCBLAT-UHFFFAOYSA-N 0.000 claims description 17
- JSXZKCAERPRSEH-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(2-methoxyethoxymethyl)phenyl]pyrimidin-2-yl]-N-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)piperidine-4-carboxamide Chemical compound COCCOCc1ccc(cc1)-c1ccnc(n1)N1CCC(F)(CC1)C(=O)NC1(C)CCN2CCC1CC2 JSXZKCAERPRSEH-UHFFFAOYSA-N 0.000 claims description 17
- BHQKXEPIAXCKKU-UHFFFAOYSA-N 4-fluoro-1-[5-fluoro-4-[4-(2-methoxyethoxymethyl)phenyl]pyrimidin-2-yl]-n-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)piperidine-4-carboxamide Chemical compound C1=CC(COCCOC)=CC=C1C1=NC(N2CCC(F)(CC2)C(=O)NC2(C)C3CCN(CC3)CC2)=NC=C1F BHQKXEPIAXCKKU-UHFFFAOYSA-N 0.000 claims description 17
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 17
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims description 16
- 238000003384 imaging method Methods 0.000 claims description 11
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical group C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims description 9
- 210000005084 renal tissue Anatomy 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 136
- 235000001014 amino acid Nutrition 0.000 description 112
- 125000003275 alpha amino acid group Chemical group 0.000 description 96
- 102000006313 Cyclin D3 Human genes 0.000 description 87
- 230000026731 phosphorylation Effects 0.000 description 73
- 238000006366 phosphorylation reaction Methods 0.000 description 73
- 235000018102 proteins Nutrition 0.000 description 55
- 102000001708 Protein Isoforms Human genes 0.000 description 47
- 108010029485 Protein Isoforms Proteins 0.000 description 47
- 125000003545 alkoxy group Chemical group 0.000 description 45
- 241000699670 Mus sp. Species 0.000 description 39
- 235000004400 serine Nutrition 0.000 description 35
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 34
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 31
- 239000004473 Threonine Substances 0.000 description 31
- 125000000217 alkyl group Chemical group 0.000 description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 24
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 20
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 19
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 19
- 125000005843 halogen group Chemical group 0.000 description 18
- 125000001072 heteroaryl group Chemical group 0.000 description 18
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 16
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 16
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 15
- 125000003118 aryl group Chemical group 0.000 description 15
- 239000006166 lysate Substances 0.000 description 14
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 13
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 12
- 230000002485 urinary effect Effects 0.000 description 11
- 102000011899 Aquaporin 2 Human genes 0.000 description 10
- 108010036221 Aquaporin 2 Proteins 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 125000000000 cycloalkoxy group Chemical group 0.000 description 9
- 208000031513 cyst Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 102000006311 Cyclin D1 Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 238000003119 immunoblot Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
- 102100032596 Fibrocystin Human genes 0.000 description 4
- 101000730595 Homo sapiens Fibrocystin Proteins 0.000 description 4
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 description 4
- UMWIMNNPYBWNRY-XMMPIXPASA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[4-[4-(2-methoxyethoxy)phenyl]phenyl]propan-2-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=CC=C(C(C)(C)NC(=O)O[C@H]2C3CCN(CC3)C2)C=C1 UMWIMNNPYBWNRY-XMMPIXPASA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 102000057397 human MAPK3 Human genes 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- FGFRLPUTEXUVNL-UHFFFAOYSA-N 1-[1-[4-(4-fluorophenyl)phenyl]cyclopropyl]-1-methyl-3-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)urea Chemical compound C1N(CC2)CCC2C1(C)NC(=O)N(C)C1(C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)CC1 FGFRLPUTEXUVNL-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001074439 Homo sapiens Polycystin-2 Proteins 0.000 description 2
- 101001026882 Homo sapiens Serine/threonine-protein kinase D2 Proteins 0.000 description 2
- 101710151833 Movement protein TGBp3 Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000005466 alkylenyl group Chemical group 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000037416 cystogenesis Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000045373 human MAPK1 Human genes 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229960004390 palbociclib Drugs 0.000 description 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 1
- KQIKMRHZEVFCCU-UHFFFAOYSA-N 1-(3-butyl-1-azabicyclo[2.2.2]octan-3-yl)-3-[4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl]urea Chemical compound C1N(CC2)CCC2C1(CCCC)NC(=O)NC(C)(C)C#CC1=CC=C(F)C=C1 KQIKMRHZEVFCCU-UHFFFAOYSA-N 0.000 description 1
- BZMZZWDYCZANBV-UHFFFAOYSA-N 1-[2-[4-(4-fluorophenyl)phenyl]propan-2-yl]-3-(5-methyl-1-azabicyclo[4.2.2]decan-5-yl)urea Chemical compound C1CCN(CC2)CCC2C1(C)NC(=O)NC(C)(C)C(C=C1)=CC=C1C1=CC=C(F)C=C1 BZMZZWDYCZANBV-UHFFFAOYSA-N 0.000 description 1
- JFEYMBFKUPANIG-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl n-[4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C#CC1=CC=C(F)C=C1 JFEYMBFKUPANIG-UHFFFAOYSA-N 0.000 description 1
- LFBSYVLYNLSQGY-UHFFFAOYSA-N 2-(2-pyrrol-1-ylpyridin-4-yl)propan-2-yl carbamate Chemical compound C(N)(OC(C)(C)C1=CC(=NC=C1)N1C=CC=C1)=O LFBSYVLYNLSQGY-UHFFFAOYSA-N 0.000 description 1
- MQVCFIOTWNYTPO-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)indazol-6-yl]propan-2-yl carbamate Chemical compound C(N)(OC(C)(C)C=1C=CC2=CN(N=C2C=1)C1=CC=C(C=C1)F)=O MQVCFIOTWNYTPO-UHFFFAOYSA-N 0.000 description 1
- MRPGRAKIAJJGMM-OCCSQVGLSA-N 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC(=CC=1)C(F)(F)F)Cl)=CC2=O MRPGRAKIAJJGMM-OCCSQVGLSA-N 0.000 description 1
- BVPMZLUEQQLULG-UHFFFAOYSA-N 2-[3-fluoro-4-(4-fluorophenyl)phenyl]propan-2-ylcarbamic acid Chemical compound FC1=CC(C(C)(NC(O)=O)C)=CC=C1C1=CC=C(F)C=C1 BVPMZLUEQQLULG-UHFFFAOYSA-N 0.000 description 1
- HIPJJISBYOOYMG-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-6-yl)phenyl]propan-2-yl carbamate Chemical compound C(N)(OC(C)(C)C1=CC=C(C=C1)C1=CC2=C(N=CS2)C=C1)=O HIPJJISBYOOYMG-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- NHEGPWLFTPOICS-UHFFFAOYSA-N 3-[4-(4-fluorophenyl)phenyl]pentan-3-yl carbamate Chemical compound C(N)(OC(CC)(CC)C1=CC=C(C=C1)C1=CC=C(C=C1)F)=O NHEGPWLFTPOICS-UHFFFAOYSA-N 0.000 description 1
- HHTWDQMTAADGQQ-UHFFFAOYSA-N 3-methyl-n-[2-(4-phenylphenyl)propan-2-ylsulfamoyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1N(CC2)CCC2C1(C)NS(=O)(=O)NC(C)(C)C(C=C1)=CC=C1C1=CC=CC=C1 HHTWDQMTAADGQQ-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 206010061803 Cyst rupture Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 1
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 description 1
- 101001072338 Homo sapiens Proliferating cell nuclear antigen Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 101710118632 Movement protein BC1 Proteins 0.000 description 1
- 208000007696 Multicystic Dysplastic Kidney Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000407 Pancreatic Cyst Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102100037312 Serine/threonine-protein kinase D2 Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 102000047723 human CCND1 Human genes 0.000 description 1
- 102000047811 human CCND3 Human genes 0.000 description 1
- 102000044255 human PCNA Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- QWTRUZKBHYEKAJ-UHFFFAOYSA-N n-[2-[4-(4-fluorophenyl)phenyl]propan-2-ylsulfamoyl]-3-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1N(CC2)CCC2C1(C)NS(=O)(=O)NC(C)(C)C(C=C1)=CC=C1C1=CC=C(F)C=C1 QWTRUZKBHYEKAJ-UHFFFAOYSA-N 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033031P | 2014-08-04 | 2014-08-04 | |
| US62/033,031 | 2014-08-04 | ||
| PCT/US2015/043497 WO2016022500A2 (en) | 2014-08-04 | 2015-08-03 | Biomarkers of polycystic kidney disease and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2015301278A1 true AU2015301278A1 (en) | 2017-02-09 |
Family
ID=54035292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015301278A Abandoned AU2015301278A1 (en) | 2014-08-04 | 2015-08-03 | Biomarkers of polycystic kidney disease and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10871495B2 (https=) |
| EP (1) | EP3177932B1 (https=) |
| JP (2) | JP6730252B2 (https=) |
| KR (1) | KR20170033436A (https=) |
| CN (1) | CN106716136B (https=) |
| AU (1) | AU2015301278A1 (https=) |
| BR (1) | BR112017002003A2 (https=) |
| CO (1) | CO2017001596A2 (https=) |
| MX (1) | MX2017001648A (https=) |
| RU (1) | RU2017106891A (https=) |
| SG (1) | SG11201700290SA (https=) |
| WO (1) | WO2016022500A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201891170A1 (ru) | 2015-11-18 | 2018-11-30 | Джензим Корпорейшн | Биомаркер поликистозной болезни почек и варианты его применения |
| GB201719520D0 (en) * | 2017-11-24 | 2018-01-10 | Univ College Cardiff Consultants Ltd | Neuroprotectvie peptide |
| KR102859441B1 (ko) * | 2019-11-22 | 2025-09-12 | 서울대학교산학협력단 | Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100708573B1 (ko) * | 1999-05-24 | 2007-04-18 | 에이브이아이 바이오파마 인코포레이티드 | 다낭 신장 질환의 치료를 위한 ｃ-ｍｙｃ에 대한 안티센스 |
| US9006181B2 (en) * | 2004-07-21 | 2015-04-14 | The Administrators Of The Tulane Educational Fund | Treatment of renal dysfunction and multiple myeloma using PACAP compounds |
| EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| US20120077263A1 (en) * | 2009-06-05 | 2012-03-29 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| CN102018702B (zh) * | 2009-09-16 | 2012-07-18 | 北京大学 | 银杏内酯b的一种用途 |
| ES2606140T3 (es) | 2010-10-01 | 2017-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente |
| US20130276513A1 (en) * | 2010-10-14 | 2013-10-24 | The Regents Of The University Of California | Methods for diagnosing and assessing kidney disease |
| US10478446B2 (en) | 2012-07-03 | 2019-11-19 | Fondazione Centro San Raffaele Office Of Biotechnology Transfer | Compounds for use in polycystic kidney disease |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
-
2015
- 2015-08-03 WO PCT/US2015/043497 patent/WO2016022500A2/en not_active Ceased
- 2015-08-03 BR BR112017002003A patent/BR112017002003A2/pt not_active Application Discontinuation
- 2015-08-03 US US15/501,496 patent/US10871495B2/en active Active
- 2015-08-03 RU RU2017106891A patent/RU2017106891A/ru not_active Application Discontinuation
- 2015-08-03 EP EP15757363.5A patent/EP3177932B1/en active Active
- 2015-08-03 AU AU2015301278A patent/AU2015301278A1/en not_active Abandoned
- 2015-08-03 JP JP2017506291A patent/JP6730252B2/ja active Active
- 2015-08-03 CN CN201580053081.4A patent/CN106716136B/zh active Active
- 2015-08-03 MX MX2017001648A patent/MX2017001648A/es unknown
- 2015-08-03 KR KR1020177005740A patent/KR20170033436A/ko not_active Withdrawn
- 2015-08-03 SG SG11201700290SA patent/SG11201700290SA/en unknown
-
2017
- 2017-02-17 CO CONC2017/0001596A patent/CO2017001596A2/es unknown
-
2020
- 2020-07-01 JP JP2020113693A patent/JP7005695B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017001648A (es) | 2017-04-27 |
| JP6730252B2 (ja) | 2020-07-29 |
| KR20170033436A (ko) | 2017-03-24 |
| JP2017525955A (ja) | 2017-09-07 |
| RU2017106891A (ru) | 2018-09-06 |
| RU2017106891A3 (https=) | 2019-03-14 |
| EP3177932A2 (en) | 2017-06-14 |
| EP3177932B1 (en) | 2021-07-14 |
| JP7005695B2 (ja) | 2022-02-04 |
| WO2016022500A2 (en) | 2016-02-11 |
| CO2017001596A2 (es) | 2017-05-19 |
| WO2016022500A3 (en) | 2016-04-07 |
| CN106716136B (zh) | 2020-06-23 |
| BR112017002003A2 (pt) | 2017-12-12 |
| CN106716136A (zh) | 2017-05-24 |
| SG11201700290SA (en) | 2017-02-27 |
| US20170227551A1 (en) | 2017-08-10 |
| JP2020170013A (ja) | 2020-10-15 |
| US10871495B2 (en) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12150938B2 (en) | Biomarker of polycystic kidney disease and uses thereof | |
| Yuan et al. | First-in-human prospective trial of sonobiopsy in high-grade glioma patients using neuronavigation-guided focused ultrasound | |
| Ling et al. | Urinary CD80 levels as a diagnostic biomarker of minimal change disease | |
| JP7005695B2 (ja) | 多発性嚢胞腎のバイオマーカーおよびその使用 | |
| Wang et al. | Mesenchymal stem cells ameliorate lipid metabolism through reducing mitochondrial damage of hepatocytes in the treatment of post-hepatectomy liver failure | |
| Weng et al. | Fiber scaffold bioartificial liver therapy relieves acute liver failure and extrahepatic organ injury in pigs | |
| Park et al. | Regulation of phosphorylation of glycogen synthase kinase 3α and the correlation with sperm motility in human | |
| JP2019502902A5 (https=) | ||
| JP2017525955A5 (https=) | ||
| Yin et al. | MMP‐7 affects peritoneal ultrafiltration associated with elevated aquaporin‐1 expression via MAPK/ERK pathway in peritoneal mesothelial cells | |
| CN116359519B (zh) | CLDN5蛋白、Cldn5基因及其修饰在抑郁障碍诊断和/或治疗中的应用 | |
| Chen et al. | Phosphate binders suppress glutaminase activity for treatment of cirrhosis and hepatic encephalopathy murine models | |
| Srivastava et al. | A COMPREHENSIVE REVIEW ON DIABETES ASSOCIATED DEMENTIA AND NEPHROPATHY: EXPLORING THE COMMON FACTORS. | |
| UA121645U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| Burris | Evaluating Cecal Ligation and Puncture-Induced Kidney Injury in Diabetic Meprin Deficient Mice | |
| UA125787U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| WO2014168508A1 (ru) | Способ диагностики нефротоксичности циклосоприна а у детей с нефротическим синдромом | |
| UA127840U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| Gerber et al. | Association of Serum Biomarkers With Fatigue in Patients With Chronic Liver Disease | |
| Park et al. | The Influence of Hemodialysis to Prognosis of Patients With Severe Alcoholic Lactic Acidosis | |
| UA125468U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| UA128173U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| UA125779U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| UA125912U (uk) | Спосіб діагностики розвитку атеросклерозу | |
| UA122012U (uk) | Спосіб діагностики розвитку атеросклерозу |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |